ASND (Ascendis Pharma AS) Change In Receivables: $-138 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASND Ascendis Pharma AS ASND
37 GF Score
Price $252.84
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Change In Receivables?

Ascendis Pharma AS ASND +0.38% 37 Change In Receivables is $-138 Mil as of Mar. 2026. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

Ascendis Pharma AS's change in receivables for the quarter that ended in Mar. 2026 was $-42 Mil. It means Ascendis Pharma AS's Accounts Receivable increased by $42 Mil from Dec. 2025 to Mar. 2026 .

Ascendis Pharma AS's change in receivables for the fiscal year that ended in Dec. 2025 was $18 Mil. It means Ascendis Pharma AS's Accounts Receivable declined by $18 Mil from Dec. 2024 to Dec. 2025 .

Ascendis Pharma AS's Accounts Receivable for the quarter that ended in Mar. 2026 was $207 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Ascendis Pharma AS's Days Sales Outstanding for the three months ended in Mar. 2026 was 66.12.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ascendis Pharma AS's liquidation value for the three months ended in Mar. 2026 was $-753 Mil.

Ascendis Pharma AS  (NAS:ASND) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ascendis Pharma AS's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=206.562/285.088*91
=66.12

2. In Ben Graham's calculation of liquidation value, Ascendis Pharma AS's accounts receivable are only considered to be worth 75% of book value:

Ascendis Pharma AS's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=662.22-1751.799+0.75 * 206.562+0.5 * 363.401
=-753

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Change In Receivables Related Terms

Ascendis Pharma AS Change In Receivables Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Change In Receivables Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.52 -12.22 -35.74 -124.20 18.25

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 105.98 -55.35 -29.24 -11.18 -42.05
ASND
37GF Score
Ascendis Pharma AS ASND
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-138 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-138 Mil mean?
Ascendis Pharma AS (ASND) has a Change In Receivables of $-138 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Change In Receivables too high?
Ascendis Pharma AS's current Change In Receivables is $-138 Mil. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Change In Receivables compare to JAZZ and BBIO?
Ascendis Pharma AS's Change In Receivables of $-138 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Change In Receivables is $-138 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Change In Receivables of $-138 Mil. The current Change In Receivables is $-138 Mil. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Change In Receivables is $-138 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges A1SN34:Brazil
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for ASND

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$252.84
Price